TABLE 1.
Radiopharmaceuticals based on 177Lu used in active, completed, and recruiting studies in the USA, Trials (2023).
| Interventions | Number of studies | Treatment conditions |
|---|---|---|
| 177Lu-DOTATATE (Lutathera) | 25 | GEP NETs |
| 177Lu-PSMA-617 (Pluvicto) | 7 | PSMA-positive mCRPC |
| 177Lu-J591 | 6 | PSMA-positive mCRPC |
| 177Lu-DOTATOC | 2 | NETs |
| 177Lu-PSMA-I&T | 2 | PSMA-positive mCRPC |
| 177Lu-DOTA-HH1 (Betalutin) | 2 | B-cell non-Hodgkin lymphomas |
| 177Lu-PNT2002 | 2 | mCRPC |
| 177Lu-DOTA-ABM-5G | 1 | advanced/metastatic PDA |
| 177Lu-DOTA-EB-TATE | 1 | metastatic NETs |
| 177Lu-CC49 | 1 | PSMA-positive mCRPC |
| CTT1403 | 1 | PSMA-positive mCRPC |
| 177Lu-DOTA-JR11 | 1 | NETs |
| 177Lu-NeoB | 1 | GRPR-positive tumors |
| 177Lu-girentuximab | 1 | metastatic ccRCC |
| GD2-SADA:177Lu-DOTA | 1 | GD2-positive Solid tumors |
| 177Lu-FAP-2286 | 1 | FAP-positive Solid tumors |
| 177Lu-Ludotadipep | 1 | mCRPC |
| 177Lu-rhPSMA-10.1 | 1 | PSMA-positive mCRPC |